Von Willebrand disease: Local diagnosis and management of a globally distributed bleeding disorder

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 440-455

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

DDAVP; desmopressin; diagnosis; factor concentrates; genetic testing; management; von Willebrand disease; VWD

Indexed keywords

ANTIFIBRINOLYTIC AGENT; C REACTIVE PROTEIN; DESMOPRESSIN; FERRITIN; FIBRINOGEN; GLYCOPROTEIN IB ALPHA; VON WILLEBRAND FACTOR;

ARTICLE; BINDING SITE; BLEEDING TIME; BLOOD CELL COUNT; BLOOD GROUP ABO SYSTEM; CLEARANCE; CONSANGUINEOUS MARRIAGE; DEVELOPING COUNTRY; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FREQUENCY ANALYSIS; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; INDIA; IRAN; LABORATORY TEST; MEDICAL CARE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCREENING TEST; THROMBIN TIME; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

ANTIFIBRINOLYTIC AGENTS; DEAMINO ARGININE VASOPRESSIN; DEVELOPING COUNTRIES; HEMOSTATICS; HUMANS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; WORLD HEALTH;

EID: 81755184051     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281028     Document Type: Article

References (78)

1. Casonato A, Daidone V, Padrini R. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. Semin Thromb Hemost 2011 37 5 456-463
2. Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011 37 5 464-469
3. Hamilton A, Ozelo M, Leggo J et al. Frequency of platelet type versus type 2B von Willebrand disease: an international registry-based study. Thromb Haemost 2011 105 3 501-508
4. Hampshire D J., Goodeve A C. The International Society on Thrombosis and Haematosis von Willebrand disease database: an update. Semin Thromb Hemost 2011 37 5 470-479
5. de Wee E M., Leebeek F WG, Eikenboom JCJ. Diagnosis and management of von Willebrand disease in the Netherlands. Semin Thromb Hemost 2011 37 5 480-487
6. Keeney S, Collins P, Cumming A, Goodeve A, Pasi J. Diagnosis and management of von Willebrand disease in the United Kingdom. Semin Thromb Hemost 2011 37 5 488-494
7. Lassila R, Holme P A., Landorph A, Petrini P, Önundarson P T., Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. Semin Thromb Hemost 2011 37 5 495-502
8. Batlle J, Perez-Rodriguez A, Prego JCP, Fraga E L., Rodriguez-Trillo A, Lopez-Fernandez M F., on behalf of participant investigators and centres. Diagnosis and management of von Willebrand disease in Spain. Semin Thromb Hemost 2011 37 5 503-510
9. Federici A B., Bucciarelli P, Castaman G, Baronciani L, Canciani M T., Mazzucconi M G., Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci P M. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1,234 patients. Semin Thromb Hemost 2011 37 5 511-521
10. James P D., Lillicrap D P. The diagnosis and management of von Willebrand disease in Canada. Semin Thromb Hemost 2011 37 5 522-527
11. Flood V H., Gill J C., Bellissimo D B., Haberichter S L., Friedman K D., Montgomery R R. von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost 2011 37 5 528-534
12. Rodgers S E., Lloyd J V., Mangos H M., Duncan E M., McRae S J. Diagnosis and management of adult patients with von Willebrand disorder in South Australia. Semin Thromb Hemost 2011 37 5 535-541
13. Favaloro E J., Bonar R, Favaloro J, Koutts J. Diagnosis and management of von Willebrand disease in Australia. Semin Thromb Hemost 2011 37 5 542-554
14. Rajagopal R, Smith M P. Diagnosis of von Willebrand disease in South Island, New Zealand. Semin Thromb Hemost 2011 37 5 555-559
15. Bonduel M, Frontroth J P., Hepner M, Sciuccati G, Feliu-Torres A, Pieroni G. von Willebrand disease in children: diagnosis and management of a pediatric cohort in one single center in Argentina. Semin Thromb Hemost 2011 37 5 560-567
16. Woods A I., Luceros A S., Meschengieser S S., Kempfer A C., Blanco A N., Lazzari M A. Diagnosis and management of von Willebrand disease in a single institution of Argentina. Semin Thromb Hemost 2011 37 5 568-575
17. Meiring M, Coetzee M, Kelderman M, Badenhorst P. Laboratory diagnosis and management of von Willebrand disease in South Africa. Semin Thromb Hemost 2011 37 5 576-580
18. Akin M, Kavakli K. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience. Semin Thromb Hemost 2011 37 5 581-586
19. Nair S C., Viswabandya A, Srivastava A. Diagnosis and management of von Willebrand disease (VWD): a developing country perspective. Semin Thromb Hemost 2011 37 5 581-586
20. Ghosh K, Shetty S. Epidemiology, diagnosis and management of von Willebrand disease in India. Semin Thromb Hemost 2011 37 5 595-601
21. Cohan N, Karimi M. Diagnosis and management of von Willebrand disease in Iran. Semin Thromb Hemost 2011 37 5 602-606
22. Xu J, Yu Z, Zhang L, Ruan C, Yang R. Diagnosis and management of von Willebrand disease in China. Semin Thromb Hemost 2011 37 5 607-614
23. Sadler J E., Budde U, Eikenboom J C. et al, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006 4 10 2103-2114 (Pubitemid 44403432)
24. Favaloro E J. Identification and functional characterisation of von Willebrand disease. US Hematology 2009 2 1 16-23
25. Favaloro E J. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009 35 1 60-75
26. Favaloro E J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 8 727-744 (Pubitemid 351158442)
27. Favaloro E J., Krigstein M, Koutts J, Brighton T, Lindeman R. Genetic testing for the diagnosis of von Willebrand disease: benefits and limitations. J Coag Disorders 2010 2 37-47
28. Favaloro E J. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010 8 1 6-12
29. Rodeghiero F, Tosetto A, Abshire T et al, ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010 8 9 2063-2065
30. Favaloro E J., Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010 48 5 579-598
31. Othman M, Favaloro E J. Genetics of type 2B von Willebrand disease: true 2B, tricky 2B, or not 2B. What are the modifiers of the phenotype? Semin Thromb Hemost 2008 34 6 520-531
32. Federici A B., Mannucci P M., Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009 113 3 526-534
33. Frontroth J P., Hepner M, Sciuccati G, Feliú Torres A, Pieroni G, Bonduel M. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost 2010 104 6 1158-1165
34. Ribba A S., Loisel I, Lavergne J M. et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001 86 3 848-854 (Pubitemid 32834196)
35. Riddell A F., Gomez K, Millar C M. et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009 114 16 3489-3496
36. Flood V H., Lederman C A., Wren J S. et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010 8 6 1431-1433
37. Melo-Nava B M., Benítez H, Palacios J J. et al. Molecular study of VWF gene from Mexican mestizo patients with von Willebrand disease, and the finding of three new mutations. Blood Cells Mol Dis 2007 39 3 361-365 (Pubitemid 47484473)
38. Favaloro E J., Mohammed S, Koutts J. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. Blood Coagul Fibrinolysis 2009 20 8 706-714
39. Favaloro E J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008 34 1 113-127
40. Sadler J E. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology (Am Soc Hematol Educ Program) 2009 106-112
41. Favaloro E J., Thom J, Baker R, Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. Blood Coagul Fibrinolysis 2000 11 8 729-737 (Pubitemid 32010207)
42. Favaloro E J., Bonar R, Marsden K, on behalf of the RCPA QAP Haemostasis Committee. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008 21 3 178-183
43. Favaloro E J., Lippi G, Adcock D M. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost 2008 34 7 612-634
44. Favaloro E J., Bonar R, Meiring M, Street A, Marsden K, RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007 98 2 346-358 (Pubitemid 47250238)
45. Favaloro E J., Bonar R, Kershaw G et al, on behalf of the RCPA QAP in Haematology. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program. Semin Thromb Hemost 2006 32 5 505-513 (Pubitemid 44157389)
46. Favaloro E J. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006 32 5 456-471 (Pubitemid 44157383)
47. Favaloro E J. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010 104 5 1009-1021
48. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006 32 5 485-491 (Pubitemid 44157386)
49. Favaloro E J. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost 2008 6 11 1999-2001 author reply 2002-2003
50. Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology (Am Soc Hematol Educ Program) 2009 113-123
51. Favaloro E J., Thom J, Patterson D et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009 123 6 862-868
52. Favaloro E J., Thom J, Patterson D et al. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. Blood Coagul Fibrinolysis 2009 20 6 475-483
53. Favaloro E J. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011 127 Suppl 2 S17-S21
54. Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M, UK Haemophilia Centre Doctors' Organisation (UKHCDO). The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia 2008 14 5 1099-1111
55. Stonebraker J S., Bolton-Maggs P H., Soucie J M., Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010 16 1 20-32
56. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987 69 2 454-459 (Pubitemid 17022013)
57. Castaman G, Eikenboom J C., Bertina R M., Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999 82 3 1065-1070 (Pubitemid 29419720)
58. Biron C, Mahieu B, Rochette A et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999 134 6 605-609
59. Werner E J., Broxson E H., Tucker E L., Giroux D S., Shults J, Abshire T C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993 123 6 893-898 (Pubitemid 23353251)
60. Gürsel T, Kavakl K, Aktulu G et al. Hemofili ve von Willebrand Hastalnda Tan ve Tedavi, Türk Hematoloji Dernei-Hemofili Alt Komitesi (Turkish Guideline). stanbul, Turkey Rehberi 1999 2-5
61. Yilmaz D, Karapnar B, Yeniay B S., Balkan C, Bilenolu B, Kavakl K. zmir'de von Willebrand Hastal skln belirtmeye yönelik epidemiyolojik çalma [in Turkish]. Ege Pediatri Bülteni 2005 12 3 151-159
62. Cabrera M E., Artigas C G., Páez E et al. von Willebrand's disease in the IX Region of Chile. Rev Med Chil 1989 117 4 423-430
63. Diez-Ewald M, Vizcaíno G, Arteaga-Vizcaíno M, Fernández N, Weir-Medina J, Gómez O. Epidemiology of von Willebrand's disease in the state of Zulia, Venezuela. Invest Clin 1991 32 4 187-199
64. Zhang L, Li H, Zhao H, Zhang X, Ji L, Yang R. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia 2003 9 6 696-702 (Pubitemid 37540810)
65. Sadler J E., Mannucci P M., Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000 84 2 160-174 (Pubitemid 30601459)
66. Iorio A, Oliovecchio E, Morfini M, Mannucci P M., Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008 14 3 444-453 (Pubitemid 351638730)
67. Canadian Hemophilia Registry. Available at: http://fhs.mcmaster.ca/chr/ data.html Accessed December 27, 2010
68. World Federation for Haemophilia. 2008 Report. Available at: www.wfh.org/2/docs/Publications/../2008-Global-Survey-Report.pdf Accessed February 18, 2011
69. Woods A I., Meschengieser S S., Blanco A N. et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease. Haematologica 2001 86 4 420-427 (Pubitemid 32428504)
70. Zhang J Y., Wang Y C., Yang L et al. Retrospective analysis of 100 patients with von Willebrand disease. Clin Focus 2003 18 581-582
71. Kumar S, Kishore R, Gupta V, Jain M, Shukla J. Prevalence and spectrum of von Willebrand disease in eastern Uttar Pradesh. Indian J Pathol Microbiol 2010 53 3 486-489
72. Trasi S, Shetty S, Ghosh K, Mohanty D. Prevalence and spectrum of von Willebrand disease from western India. Indian J Med Res 2005 121 5 653-658 (Pubitemid 40846819)
73. Rezende S M., Pinheiro K, Caram C, Genovez G, Barca D. Registry of inherited coagulopathies in Brazil: first report. Haemophilia 2009 15 1 142-149
74. Tagliaferri A, Rivolta G F., Biasoli C et al. A web-based registry of inherited bleeding disorders in the region of Emilia-Romagna: results at three and a half years. Haemophilia 2008 14 2 343-354 (Pubitemid 351338696)
75. Michiels J J., van de Velde A, van Vliet H H., van der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002 28 2 111-132
76. Michiels J J., van Vliet H H., Berneman Z et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost 2007 13 1 14-34 (Pubitemid 44905280)
77. Federici A B., Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004 103 6 2032-2038 (Pubitemid 38326217)
78. Lee C A., Hubbard A, Sabin C A. et al, on behalf of the ISTH-SSC sub-committee on VWF. Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. J Thromb Haemost 2010 9 220-222